Termine
Performance
26.11.2021

07.10.21 Sberbank
Regulatory Reporting
07.10.21 Sberbank
Regulatory Reporting
07.10.21 VMware, Inc.
Analysts' Conference
07.10.21 Ströer SE & Co. KGaA
Ströer Capital Markets Day 2021
07.10.21 TAKKT AG
Messe
07.10.21 Deutsche Konsum REIT-AG
Roadshow
07.10.21 centrotherm international AG
Veröffentlichung Halbjahresabschluss
07.10.21 Heidelberg Pharma AG
Veröffentlichung Quartalsmitteilung (Stichtag Q3)
07.10.21 APEX Energy Teterow GmbH
Sonstige
07.10.21 APEX Energy Teterow GmbH
Sonstige

November

KW M D M D F S S
44 1 2 3 4 5 6 7
45 8 9 10 11 12 13 14
46 15 16 17 18 19 20 21
47 22 23 24 25 26 27 28
48 29 30          

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021